Removal of phosphate from lipid a as a strategy to detoxify lipopolysaccharide

被引:165
作者
Bentala, H [1 ]
Verweij, WR [1 ]
Huizinga-Van der Vlag, A [1 ]
van Loenen-Weemaes, AM [1 ]
Meijer, DKF [1 ]
Poelstra, K [1 ]
机构
[1] Univ Groningen, Ctr Pharm, Dept Pharmacokinet & Drug Delivery, Inst Drug Explorat, NL-9713 AV Groningen, Netherlands
来源
SHOCK | 2002年 / 18卷 / 06期
关键词
alkaline phosphatase; sepsis; endotoxin; TNF alpha; nitric oxide; reactive oxygen species; RAW; 264.7; cells;
D O I
10.1097/00024382-200212000-00013
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Lipopolysaccharide (LPS) may cause sepsis when it enters the blood circulation. The toxic moiety of LPS is the well-preserved lipid A part. Lipid A contains two phosphate groups attached to diglucosamine, which are crucial for the many biological activities of LIPS. In previous studies we found that alkaline phosphatase (AP) was able to dephosphorylate LPS. To test whether LPS-dephosphorylation can be used for intervention during sepsis, we investigated the effects of Salmonella minnesota Re 595 LIPS and its dephosphorylated counterpart monophosphoryl lipid A (MPLA) on macrophage activation in vivo and in vitro. Exposure of RAW264.7 cells to LPS induced high levels of tumor necrosis factor (TNFalpha) and nitric oxide (NO), whereas MPLA elicited no response. LPS in vivo induced a significant rise in TNFa levels in mice and an enhanced inflammatory cell influx in the lung, whereas MPLA did not. Having shown the relevance of this particular phosphate group of LIPS, we subsequently explored the ILPS-dephosphorylating ability of AP in different tissues, and the effect of AP administration in mice challenged with LIPS. Histochemical data show that AP dephosphorylated native LPS in all tissues examined, whereas MPLA was not dephosphorylated. When mice received AP immediately after the LIDS challenge, the survival rate was 100%, over 57% in the control group. We conclude that the enzymatic removal of phosphate groups from LPS by AP represents a crucial detoxification reaction, which may provide a new strategy to treat LPS-induced diseases like sepsis.
引用
收藏
页码:561 / 566
页数:6
相关论文
共 31 条
  • [1] EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL
    ABRAHAM, E
    WUNDERINK, R
    SILVERMAN, H
    PERL, TM
    NASRAWAY, S
    LEVY, H
    BONE, R
    WENZEL, RP
    BALK, R
    ALLRED, R
    PENNINGTON, JE
    WHERRY, JC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12): : 934 - 941
  • [2] A RECOMBINANT HUMAN RECEPTOR ANTAGONIST TO INTERLEUKIN-1 IMPROVES SURVIVAL AFTER LETHAL ENDOTOXEMIA IN MICE
    ALEXANDER, HR
    DOHERTY, GM
    BURESH, CM
    VENZON, DJ
    NORTON, JA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (04) : 1029 - 1032
  • [3] PRETREATMENT OF NORMAL HUMANS WITH MONOPHOSPHORYL LIPID-A INDUCES TOLERANCE TO ENDOTOXIN - A PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, CONTROLLED TRIAL
    ASTIZ, ME
    RACKOW, EC
    STILL, JG
    HOWELL, ST
    CATO, A
    VONESCHEN, KB
    ULRICH, JT
    RUDBACH, JA
    MCMAHON, G
    VARGAS, R
    STERN, W
    [J]. CRITICAL CARE MEDICINE, 1995, 23 (01) : 9 - 17
  • [4] BAHRANI S, 1996, PATHOLOGY SEPTIC SHO, P239
  • [5] ASSOCIATION BETWEEN PROTECTIVE EFFICACY OF ANTI-LIPOPOLYSACCHARIDE (LPS) ANTIBODIES AND SUPPRESSION OF LPS-INDUCED TUMOR NECROSIS FACTOR-ALPHA AND INTERLEUKIN-6
    BAUMGARTNER, JD
    HEUMANN, D
    GERAIN, J
    WEINBRECK, P
    GRAU, GE
    GLAUSER, MP
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 171 (03) : 889 - 896
  • [6] Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard, GR
    Vincent, JL
    Laterre, P
    LaRosa, SP
    Dhainaut, JF
    Lopez-Rodriguez, A
    Steingrub, JS
    Garber, GE
    Helterbrand, JD
    Ely, EW
    Fisher, CJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) : 699 - 709
  • [7] A 2ND LARGE CONTROLLED CLINICAL-STUDY OF E5, A MONOCLONAL-ANTIBODY TO ENDOTOXIN - RESULTS OF A PROSPECTIVE, MULTICENTER, RANDOMIZED, CONTROLLED TRIAL
    BONE, RC
    BALK, RA
    FEIN, AM
    PERL, TM
    WENZEL, RP
    REINES, HD
    QUENZER, RW
    IBERTI, TJ
    MACINTYRE, N
    SCHEIN, RMH
    TRENHOLME, G
    NIEDERMAN, M
    CHALFIN, D
    ABALOS, A
    OROPELLO, J
    EMPSON, P
    CAMINITII, S
    GREENMAN, R
    BOOTH, F
    PLOUFFE, J
    RUSSELL, J
    GIANAKOPOULOS, G
    IANNINI, P
    HINDES, R
    COBLENS, K
    KOHLER, R
    MARTIN, M
    BERNARD, G
    EDWARDS, J
    CRISLIP, M
    FILLER, S
    NASRAWAY, SA
    SIGEL, PK
    SOTTILE, FD
    MARTIN, DH
    DEBOISBLANC, BP
    CHANDRASEKAR, PH
    BROUGHTON, WA
    MIDDLETON, RM
    SEIBERT, AF
    EMMANUEL, G
    LIE, TH
    ANDERSON, CLV
    PANKEY, GA
    ANDERSON, P
    OLSEN, K
    SANPEDRO, GS
    GRAHAM, D
    GROSSMAN, J
    WELS, PB
    [J]. CRITICAL CARE MEDICINE, 1995, 23 (06) : 994 - 1006
  • [8] DERMOHLEN MA, 1995, BLOOD, V85, P3437
  • [9] Dinarello CA, 1996, CURR TOP MICROBIOL, V216, P133
  • [10] EXPRESSION OF INTESTINAL ALKALINE-PHOSPHATASE IN HUMAN ORGANS
    DOMAR, U
    NILSSON, B
    BARANOV, V
    GERDES, U
    STIGBRAND, T
    [J]. HISTOCHEMISTRY, 1992, 98 (06) : 359 - 364